Patrick Daly

Urban Health Today

Study authors, led by Maria-Alexandra Papadimitriou, stated that the widely heterogeneous response to multiple myeloma (MM) treatments has limited providers&rsquo; abilities to accurately predict prognosis and individualize therapies. Papadimitriou and colleagues miRNA-sequenced patients with MM to identify potentially valuable prognostic markers.According to the report in the <a href="https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-04034-5" target="_blank" rel="noopener">Journal of Translational Medicine</a>, upregulation of miR-25 in CD138+ bone marrow plasma cells from patients with MM was a strong independent predictor for poor treatment response and disease progression among this population.<h3>miR-25 Plasma Levels Strongly Correlated With MM Outcomes</h3>Initially, researchers sequenced plasma cells from 24 patients with MM and 24 with smoldering MM (sMM) to characterize miRNA profiles. They then used in-house real-time-qPCR assays to assess levels of CD138+ and circulating miR-25 in CD138+ plasma cells from a screening cohort of 167 patients, of which 69 also had available MM peripheral plasma samples.Investigators found miR-25 in CD138+ plasma cells was upregulated for patients with MM versus sMM, Revised International Staging System (R-ISS) stage II/III versus R-ISS stage I disease, and progression versus no progression.In the screening cohort analysis, CD138+ miR-25 levels were associated with short-term progression (hazard ratio [HR], 2.729; P=.009) and poor survival (HR, 4.581; P=.004). The authors added that these findings were verified in 2 external validation cohorts with 760 (HR, 1.414; P=.039) and 149 patients (HR, 1.878; P=.005).Papadimitriou and colleagues ultimately suggested that pre-treatment miR-25 plasma levels effectively predict worse outcomes, &ldquo;serving as [a] potent non-invasive molecular tool in ameliorating MM patients&rsquo; risk-stratification and prognosis.&rdquo;Related:&nbsp;<a href="https://urbanhealthtoday.com/post/meta-analysis-the-significance-of-thrombosis-in-multiple-myeloma">The Significance of Thrombosis in Multiple Myeloma</a>

Lou Portero

Hidden Dangers: The Blood Sugar Crisis in Modern Breast Cancer Treatment

Diabetes in Women

New ACG Guidelines Address Critical Gastric Cancer Disparities in Non-White Americans

Gastroenterology

Ultra-Processed Foods Linked to Increased Ovarian and Breast Cancer Risk

Gynecologic Cancer

Latest News

Can miRNAs Predict MM Treatment Response?

Multiple Myeloma

Study finds upregulation of CD138+ plasma miR-25 is significantly common and predicts poor treatment response in MM.

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe